Igantet

Human Tetanus Immunoglobulin, the active ingredient in Igantet, is an immunoglobulin presented as an injectable solution for intramuscular use. It provides passive immunity to neutralize tetanus toxin and is used in individuals at risk of tetanus infection. GNH USA supplies Igantet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Igantet is a human immunoglobulin used in tetanus prophylaxis and related clinical pathways. - Prevention of tetanus in susceptible individuals: delivers immediate neutralisation of tetanus toxin before exposure. - Post‑exposure prophylaxis for tetanus: administered after injury to prevent toxin‑mediated disease. - Wound management when immunisation status is unknown or incomplete: supplies rapid passive protection pending active vaccination.

Adverse reactions may occur following intramuscular injection of Igantet.

Common Side Effects: - Injection site pain or tenderness - Redness or swelling at the injection site - Mild fever or chills - Headache - Nausea or gastrointestinal discomfort - Transient rash or urticaria

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Serum sickness‑like illness - Aseptic meningitis - Hemolysis or severe hemolytic anemia - Thrombotic events - Severe hypotension or shock

Prior to administration, clinicians should consider several safety measures. - Immunisation history: verify tetanus vaccination status and need for passive immunisation. - Hypersensitivity screening: avoid in patients with known IgA deficiency or severe allergic reactions to human immunoglobulins. - Monitoring: observe for immediate allergic responses during and after injection. - Concomitant therapies: assess potential interactions with other immunoglobulin products. - Aseptic technique: ensure sterile preparation and administration to prevent contamination. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Tetanus Immunoglobulin may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid): - Concurrent use of other human immunoglobulin preparations: may reduce efficacy of each product. - Live attenuated vaccines administered within 3 months: may diminish vaccine response.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor for altered bleeding risk. - Immunosuppressive drugs (e.g., corticosteroids): may affect duration of passive immunity. - Other vaccines given within 2 weeks: assess timing to avoid interference with immune response.